Αρχική World News Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed... World News Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma Από Ogkologos - 18 Δεκεμβρίου, 2025 518 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Patient Guide in Hepatocellular Carcinoma Now Available Also in German 16 Δεκεμβρίου, 2025 Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... 19 Δεκεμβρίου, 2022 At 27, She Was Told She Was Too Young For Breast... 6 Φεβρουαρίου, 2020 Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 12 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS Workout Wednesdays – Chest Exercises Part 1 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... Withdrawal of the Application to Change the EMA Marketing Authorisation for...